With the peak of generic competition for patented drugs in the past, the pharmaceutical industry is poised for sustained growth that will reach a total value of $895 billion in the next five years, according to the annual World Preview by the research firm Evaluate. The report predicts that, by 2018, biological products will constitute half of the sales of the top 100 products worldwide, Novartis will be the world's largest pharmaceutical firm, AbbVie's tumor necrosis inhibitor Humira will be the biggest-selling drug product, and anticoagulant therapies will become the fastest-growing sector, increasing more than 11% in five years.

Full Story:
PharmaTimes (U.K.)

Related Summaries